ALGN vs. ALNY: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALGN and ALNY, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
ALNY stands out with 38.15 billion USD in market value—about 3.06× ALGN’s market cap of 12.46 billion USD.
ALGN’s beta of 1.68 points to much larger expected swings compared to ALNY’s calmer 0.17, suggesting both higher upside and downside potential.
| Symbol | ALGN | ALNY |
|---|---|---|
| Company Name | Align Technology, Inc. | Alnylam Pharmaceuticals, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Devices | Biotechnology |
| CEO | Mr. Joseph M. Hogan | Dr. Yvonne L. Greenstreet M.B.A., M.D. |
| Price | 171.91 USD | 292.58 USD |
| Market Cap | 12.46 billion USD | 38.15 billion USD |
| Beta | 1.68 | 0.17 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | January 30, 2001 | June 1, 2004 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALGN and ALNY over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALGN and ALNY based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ALNY shows a negative P/E of -140.68, highlighting a year of losses, whereas ALGN at 30.88 trades on solid profitability.
- ALNY shows a negative forward PEG of -38.16, signaling expected earnings contraction, while ALGN at 2.92 maintains analysts’ projections for stable or improved profits.
- ALNY reports a negative Price-to-Free Cash Flow ratio of -506.05, showing a cash flow shortfall that could threaten its operational sustainability, while ALGN at 19.76 maintains positive cash flow.
| Symbol | ALGN | ALNY |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 30.88 | -140.68 |
| Forward PEG Ratio (TTM) | 2.92 | -38.16 |
| Price-to-Sales Ratio (P/S, TTM) | 3.13 | 16.25 |
| Price-to-Book Ratio (P/B, TTM) | 3.33 | 328.68 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 19.76 | -506.05 |
| EV-to-EBITDA (TTM) | 14.56 | -251.73 |
| EV-to-Sales (TTM) | 2.94 | 16.37 |
| EV-to-Free Cash Flow (TTM) | 18.56 | -509.80 |
Dividend Comparison
Neither ALGN nor ALNY currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
| Symbol | ALGN | ALNY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALGN and ALNY, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ALNY is highly leveraged (debt-to-equity ratio 11.28), elevating both potential gains and risks, compared to ALGN at 0.03, which maintains a steadier capital structure.
- ALGN shows “--” (minimal interest expense), but ALNY is in the red with interest coverage -0.79, signaling a net operating loss.
| Symbol | ALGN | ALNY |
|---|---|---|
| Current Ratio (TTM) | 1.21 | 3.04 |
| Quick Ratio (TTM) | 1.08 | 2.98 |
| Debt-to-Equity Ratio (TTM) | 0.03 | 11.28 |
| Debt-to-Assets Ratio (TTM) | 0.02 | 0.31 |
| Interest Coverage Ratio (TTM) | -- | -0.79 |